Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Zhaoke Ophthalmology Says IND Application Of Nvk-002 For Phase Iii Trial In China Accepted For Review

July 15 (Reuters) - Zhaoke Ophthalmology Ltd  6622.HK :
    * ZHAOKE OPHTHALMOLOGY LTD -  IND APPLICATION OF NVK-002 FOR
PHASE
III CLINICAL TRIAL IN CHINA ACCEPTED FOR REVIEW BY CENTER FOR
DRUG EVALUATION


Further company coverage:  6622.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zhaoke Ophthalmology

See all news